.png?width=251&height=42&name=download%20(32).png "download (32)"){kind=small}
%201.png "Logo (10) 1")
Invest in Cutting Edge Tech for human and animal Biopharma Manufacturing
Unlock an unparalleled investment opportunity with a team that’s revolutionizing testing in biopharma manufacturing.
Want to learn more? Download our report below!
MiQLab Systems shown are the current model which will serve as the basis for rebuilding the next generation system.
A Game-Changing Microbial Contamination Detection Solution
LexaGene is an early-stage company pioneering an innovative PCR-based solution that’s poised to revolutionize microbial contaminant detection: the MiQLab® System.
To date, the company has invested $40 million in research and development. The current leadership will take the work done to date, as well as inputs from industry research, feasibility studies, and leading biopharma customers to build a second generation of the product that meets current and future needs.
This is where our investors come in.
LexaGene’s biologics in-process manufacturing microbial contamination detection market has an estimated annual TAM of ~$2.0 billion.
The company presents an opportunity to save biopharma companies millions of dollars.
The market need has been confirmed by feasibility studies and market research with leading biopharma manufacturers.
A New Technology that Will Redefine an Industry
The MiQLab® system was designed to address a common challenge in the biopharma manufacturing process: microbial contamination.
In its current state, the MiQLab® is a broader spectrum, faster, and easier to use than existing microbial contamination detection products — and it can test more in one sample.
With our system, users get results in just two hours, instead of 28 days — that’s 300 times faster than other testing solutions. Plus, its intuitive design reduces the hands-on time to under a minute.
The next generation MiQLab® system will be incredibly appealing to a large collection of potential customers including Johnson & Johnson, Pfizer, Merck, Bristol Myers Squibb, and more.
Solving A Real Problem for Biopharma Manufacturers
One of the biggest challenges for biopharma manufacturers is the detection lag for microbial contaminants. Most detection solutions take between 14–28 days to produce results, and that can be expensive — especially when a company has to dispose of products after a contaminant is identified.
A faster, more accurate solution like the MiQLab® system can help reduce these risks while also improving the safety of medications for people, pets, and food production animals.
We’ve validated this challenge through feasibility studies with two leading biopharma manufacturers, additional market research, and direct discussions with another large biopharma company’s manufacturing and quality leadership team.
The Team
LexaGene is led by a team of seasoned executives dedicated to reshaping and
refocusing the company and its product development for success.
refocusing the company and its product development for success.
LexaGene Investors Only Stand to Win
We invite you to participate early in LexaGene’s vision and get direct access to growth potential in a massive addressable market. Through our Regulation D offering, you can own a piece of this potentially game-changing business.
If fully funded at $10 million, the RD Investors will own twenty-five percent (25%) of LexaGene Life Sciences, LLC. The membership units carry a liquidation preference, meaning that the shares receive the first cash to be distributed to shareholders from operations or from a capital event in order to return the initial investment made by the RD Investor. This liquidation preference results in these investors receiving priority distributions before any other class of investor.
In addition, LexaGene is also offering perks for their Regulation D investors. For a $100,000 investment, investors will get preferred rights during the planned second capital raise, before we seek additional investors. They will be able to purchase the same shares at a price that’s at a 25% discount to the new share price, up to the amount of their initial investment.
Anyone who invests $250,000 will have the preferred right to purchase the same shares/price basis up to the amount of their initial investment regardless of the current interest price, before we seek additional investors.
If fully funded at $10 million, the RD Investors will own twenty-five percent (25%) of LexaGene Life Sciences, LLC. The membership units carry a liquidation preference, meaning that the shares receive the first cash to be distributed to shareholders from operations or from a capital event in order to return the initial investment made by the RD Investor. This liquidation preference results in these investors receiving priority distributions before any other class of investor.
In addition, LexaGene is also offering perks for their Regulation D investors. For a $100,000 investment, investors will get preferred rights during the planned second capital raise, before we seek additional investors. They will be able to purchase the same shares at a price that’s at a 25% discount to the new share price, up to the amount of their initial investment.
Anyone who invests $250,000 will have the preferred right to purchase the same shares/price basis up to the amount of their initial investment regardless of the current interest price, before we seek additional investors.
Top 8 Reasons to Invest
LexaGene offers significant market potential, an experienced
management team, as well as broad applicability.
management team, as well as broad applicability.
1. Growing applicability
An estimated annual 350-450M tests for microbial contamination detection in the manufacturing of regulated healthcare products with biologics manufacturing estimated to be one-third of the total.
2. Multiple markets
The MiQLab® system will facilitate the safe and fast availability of medications needed by people and pets.
3. A validated market need
LexaGene has validated the need for the MiQLab® system via two feasibility studies with leading biopharma manufacturers, additional market research, and direct discussions with a large biopharma company.
4. A strong foundation
Building on the $40 million that has already been invested in R&D, as well as key patents, LexaGene is poised to develop the next version of the product.
5. A massive market
LexaGene’s biologics in-process manufacturing microbial contamination detection market has an estimated annual TAM of ~$2.0 billion.
6. A recurring revenue model
Our revenue model will include system sales and recurring revenue of consumables and service agreements. It’s the razor, razor blade model.
7. Experienced leadership
LexaGene has assembled a team of seasoned executives to reshape and refocus the company and its microbial detection product development for success.
8. Expansive insight
The LexaGene leadership team brings proven expertise in areas such as medical technology, biopharma, capital formation, and more.
Recent News from LexaGene
%202.svg "Logo (10) 2")
The Time to Invest Is Now
The need for the MiQLab® system is clear. We’ve taken the time to validate the value of our solution and now we’re on track to bring the next generation of our product.
There’s a massive market opportunity ripe for the picking, and we’re excited to take our investors with us as we capture our market share. We’re looking for early-stage investors to join us as we bring a revolutionary solution to an expectant market. Is that you?
Unlock an unparalleled investment opportunity with a promising early stage company that seeks to revolutionize microbial detection.